Table 2 Baseline characteristics and antibody titers among patients treated with anti-inflammatory treatment and matched control
Anti-inflammatory Treatment (n = 29) | Matched Control (n = 29) | P value | |
|---|---|---|---|
Age, median (IQR), y | 67 (55–73) | 70 (56–72) | 0.86 |
Male sex (%) | 11 (38) | 11 (38) | 1.0 |
Anti-inflammatory treatment | |||
Antimetabolites and OCS | 21 | NA | |
Rituximab | 8 | ||
Daily OCS dose (mg), median (IQR) | 8 (5–8) | ||
Daily mycophenolate mofetil dose (g), median (IQR) | 2 (1–2) | ||
Rituximab doses, median (IQR) | 3 (2–4) | ||
Days post last rituximab treatment, median (IQR) | 123 (36–147) | ||
IgG titer, median (IQR), Au/ml | 39.60 (4.25–165) | 970.10 (505–1926) | < 0.001 |
IgG titer GMT (SD) | 23.70 ± 12.73 | 1006.93 ± 2.45 | < 0.001 |
Seropositive (%) | 14 (48.3) | 29 (100) | < 0.001 |
Days post vaccination, median (IQR) | 179 (168–184) | 137 (122–158) | < 0.001 |